New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness analysis led by researchers at The University of Texas MD Anderson Cancer Center.



from The Medical News http://ift.tt/1AzqLLr